Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 6/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | OXTR | P30559 | 2/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6730834 | 0.87 | GRM2 (0.54) | GRM2PGROXTRAVPR1AMMP2 | |
| SCHEMBL6734943 | 0.87 | GRM2 (0.47) | GRM2PGROXTRAVPR2AVPR1A | |
| SCHEMBL6739470 | 0.86 | GRM2 (0.63) | GRM2PGROXTRMMP2MMP9 | |
| SCHEMBL6730872 | 0.86 | GRM2 (0.47) | GRM2OXTRBRD4KMT2ASMN1; SMN2 | |
| SCHEMBL6732783 | 0.82 | OXTR (0.51) | GRM2PGROXTRKMT2AMEN1 | |
| SCHEMBL6735185 | 0.82 | GRM2 (0.56) | GRM2PGR | |
| SCHEMBL6727539 | 0.81 | SYK (0.44) | GRM2OXTRAVPR2AVPR1ABRD4 | |
| SCHEMBL6727564 | 0.81 | GRM2 (0.60) | GRM2PGROXTRMMP2MMP9 | |
| SCHEMBL6735511 | 0.81 | HTT (0.56) | GRM2OXTRBRD4KMT2AALDH1A1 | |
| SCHEMBL6736493 | 0.81 | GRM2 (0.57) | GRM2PGROXTRMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800651-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-10-05 | — | — | US | claimed |
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | claimed |
| EP-1255735-A2 | PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001056990-A2 | PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | GRM2 3/4885PGR 697/4885OXTR 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.